Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lamivudine and Therapeutic Vaccine in Chronic Hepatitis B
NCT00120796Phase 3Terminated
- Sponsor
- ANRS
- Start
- Aug 2005
- Primary completion
- Jul 2008
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of hepatitis B vaccine recombinant in Chronic Hepatitis B (CHB) (2 arms), sponsored by ANRS. Primary endpoint: Undetectability of HBV DNA blood level at 12 months. Started Aug 2005; status: terminated.
02
Drugs
hepatitis B vaccine recombinant
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT00120796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00120796.